AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Crispr Therapeuticsbluebird bioHalozyme TherapeuticsAllogene TherapeuticsAudentes Therapeutics
SymbolNASDAQ:CRSPNASDAQ:BLUENASDAQ:HALONASDAQ:ALLONASDAQ:BOLD
Price Information
Current Price$64.58$63.63$24.27$48.16$59.97
52 Week RangeBuyBuyBuyBuyHold
Beat the Market™ Rank
Overall Score1.41.62.21.30.9
Analysis Score3.44.43.42.41.1
Community Score2.53.02.62.32.6
Dividend Score0.00.00.00.00.0
Ownership Score1.00.03.02.01.0
Earnings & Valuation Score0.00.61.90.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$74.42$115.47$28.63$42.75$50.75
% Upside from Price Target15.24% upside81.47% upside17.94% upside-11.23% downside-15.37% downside
Trade Information
Market Cap$3.81 billion$3.43 billion$3.26 billion$6.14 billion$2.77 billion
Beta2.262.381.751.72.18
Average Volume1,021,9731,253,7281,717,554875,1921,504,389
Sales & Book Value
Annual Revenue$289.59 million$44.67 million$195.99 millionN/AN/A
Price / Sales13.6179.2716.82N/AN/A
Cashflow$1.31 per shareN/AN/AN/AN/A
Price / Cash49.29N/AN/AN/AN/A
Book Value$14.52 per share$20.13 per share$0.43 per share$4.84 per share($7.48) per share
Price / Book4.453.1656.44N/AN/A
Profitability
Net Income$66.86 million$-789,610,000.00$-72,240,000.00$-184,590,000.00$-128,820,000.00
EPS$1.17($14.31)($0.50)($1.83)($3.40)
Trailing P/E Ratio86.11N/AN/AN/AN/A
Forward P/E RatioN/AN/A15.56N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins15.73%-1,531.04%-48.75%N/AN/A
Return on Equity (ROE)6.54%-60.05%-48.92%-33.05%N/A
Return on Assets (ROA)5.54%-46.17%-17.36%-29.27%-38.00%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.16%6.66%0.08%N/A
Current Ratio16.87%5.25%11.14%18.81%12.80%
Quick Ratio16.87%5.25%10.15%18.81%12.79%
Ownership Information
Institutional Ownership Percentage57.96%N/A95.37%57.93%96.33%
Insider Ownership Percentage21.40%3.00%2.60%36.50%5.30%
Miscellaneous
Employees1881,090281122207
Shares Outstanding61.02 million55.65 million135.82 million125.33 million46.27 million
Next Earnings Date8/3/2020 (Estimated)8/6/2020 (Estimated)8/4/2020 (Estimated)8/5/2020 (Estimated)N/A
OptionableOptionableOptionableOptionableNot OptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.